Proof of concept evaluation of a novel breast cancer therapeutic

最近的研究表明，癌细胞表面的受体，称为血管紧张素- ii型I受体（AT1R）的过度激活，触发生物信号通路，在许多癌症相关过程中发挥作用，包括肿瘤生长，血管生成，耐药性和转移。aTen Therapeutics正在开发一种新的治疗性抗体，该抗体靶向并阻断由AT1R介导的癌症相关信号，以治疗乳腺癌。该项目是开发一种创新的乳腺癌治疗方法的重要一步，有可能成为一种重要的新药，以改善患者的生活质量和延长患者的生命。

Recent research has suggested that the over activation of a receptor on the surface of cancer cells, called the angiotensin-II type I receptor (AT1R), triggers biological signalling pathways that play a role in many cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis.aTen Therapeutics is developing a novel therapeutic antibody that targets and blocks cancer-related signalling mediated by the AT1R in order to treat breast cancer. This project is a vital step in the development of an innovative breast cancer therapy with the potential to become a major new drug to improve the quality and duration of patients' lives.